ReviewCurrent pain and headache reports2018
Medical Cannabis for Neuropathic Pain.
Review in Current pain and headache reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04398446 (Coala-T-CBD Study), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Coala-T-CBD Study: A Study of the Effect of Hemp-CBD on the Severity and Duration of Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Neurotoxic Chemotherapy for Non-Metastatic Breast, Uterine, Pancreatic, and Colorectal Cancer and All Stages of Ovarian Cancer
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Are Cannabis-Based Medicines a Useful Treatment for Neuropathic Pain? A Systematic Review.Biomolecules · 2025Pooled it
- Topical Cannabidiol for Established Chemotherapy-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Trial.Cannabis and cannabinoid research · 2024Trial
- Real-Time and Long-Term Effects of Medical Marijuana on Older Adults: Protocol for a Prospective Cohort Study.JMIR research protocols · 2026Article
- Synthesis and Biological Evaluation of Tetrahydroisoquinoline Derivatives as Trypanocidal Agents.ACS omega · 2026Article
- Medical cannabis authorization and opioid milligram equivalents over time in patients with chronic pain: a retrospective analysis.Pain medicine (Malden, Mass.) · 2026Article
- Delta-9-tetrahydrocannabinol and Cannabidiol for Pain: Preclinical and Clinical Models.Current topics in behavioral neurosciences · 2026Review
- Natural Products Derived from Cannabis sativa for Pain Management.Handbook of experimental pharmacology · 2025Review
- Full-spectrum cannabis extracts for women with chronic pain syndromes: a real-life retrospective report of multi-symptomatic benefits after treatment with individually tailored dosage schemes.Frontiers in pharmacology · 2025Article
- Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts.Pain and therapy · 2024Review
- Perspectives of people with spinal cord injury on a pain education resource.Frontiers in public health · 2024Article
- Cannabinoids, Endocannabinoids, and Synthetic Cannabimimetic Molecules in Neuromuscular Disorders.International journal of molecular sciences · 2023Review
- Relief of nocturnal neuropathic pain with the use of cannabis in a patient with Fabry disease.Molecular genetics and metabolism reports · 2023Article
- Expression of Cannabinoid Receptors in the Trigeminal Ganglion of the Horse.International journal of molecular sciences · 2023Article
- Neuropathic Pain in the Emergency Setting: Diagnosis and Management.Journal of clinical medicine · 2023Review
- Olfactory ensheathing cells and neuropathic pain.Frontiers in cell and developmental biology · 2023Review
- Neuropathic pain: Mechanisms and therapeutic strategies.Frontiers in cell and developmental biology · 2023Review
- Combinations of Cannabidiol and ΔBiomedicines · 2022Article
- Review
- Article
- Clinical Outcome Data of First Cohort of Chronic Pain Patients Treated With Cannabis-Based Sublingual Oils in the United Kingdom: Analysis From the UK Medical Cannabis Registry.Journal of clinical pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewMany cultures throughout history have used cannabis to treat a variety of painful ailments. Neuropathic pain is a complicated condition that is challenging to treat with our current medications. Recent scientific discovery has elucidated the intricate role of the endocannabinoid system in the pathophysiology of neuropathic pain. As societal perceptions change, and legislation on medical cannabis relaxes, there is growing interest in the use of medical cannabis for neuropathic pain. RECENT
findingsWe examined current basic scientific research and data from recent randomized controlled trials (RCTs) evaluating medical cannabis for the treatment of neuropathic pain. These studies involved patients with diverse etiologies of neuropathic pain and included medical cannabis with different THC concentrations and routes of administration. Multiple RCTs demonstrated efficacy of medical cannabis for treating neuropathic pain, with number needed to treat (NNT) values similar to current pharmacotherapies. Although limited by small sample sizes and short duration of study, the evidence appears to support the safety and efficacy of short-term, low-dose cannabis vaporization and oral mucosal delivery for the treatment of neuropathic pain. The results suggest medical cannabis may be as tolerable and effective as current neuropathic agents; however, more studies are needed to determine the long-term effects of medical cannabis use. Furthermore, continued research to optimize dosing, cannabinoid ratios, and alternate routes of administration may help to refine the therapeutic role of medical cannabis for neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.